UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 332

Sortiert nach

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

Drugs (New York, N.Y.), 2018-03, Vol.78 (4), p.463-478

2018

Link zum Volltext

Verfügbarkeit prüfen

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Blood, 2016-06, Vol.127 (26), p.3360-3368

2016

Link zum Volltext

Verfügbarkeit prüfen

Improved differential diagnosis of intracardiac and extracardiac shunts using acoustic intensity mapping of saline contrast studies

European heart journal cardiovascular imaging, 2020-03, Vol.21 (3), p.307-317

2020

Link zum Volltext

Verfügbarkeit prüfen

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Blood, 2012-05, Vol.119 (19), p.4375-4382

2012

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

British journal of haematology, 2019-05, Vol.185 (3), p.492-502

2019

Link zum Volltext

Verfügbarkeit prüfen

GIRK currents in VTA dopamine neurons control the sensitivity of mice to cocaine-induced locomotor sensitization

Proceedings of the National Academy of Sciences - PNAS, 2018-10, Vol.115 (40), p.E9479-E9488

2018

Link zum Volltext

Verfügbarkeit prüfen

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

American journal of hematology, 2018-10, Vol.93 (10), p.1199-1206

2018

Link zum Volltext

Verfügbarkeit prüfen

Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study

Future oncology (London, England), 2022-04, Vol.18 (12), p.1499-1510

2022

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2484-2492

2016

Link zum Volltext

Verfügbarkeit prüfen

Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?

Future oncology (London, England), 2024-03, Vol.20 (9), p.481-491

2024

Link zum Volltext

Verfügbarkeit prüfen

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

Cancer, 2020-10, Vol.126 (19), p.4332-4340

2020

Link zum Volltext

Verfügbarkeit prüfen

Demystifying biosimilars: development, regulation and clinical use

Future oncology (London, England), 2019-03, Vol.15 (7), p.777-790

2019

Link zum Volltext

Verfügbarkeit prüfen

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

Supportive care in cancer, 2022-10, Vol.30 (10), p.7913-7922

2022

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Leukemia & lymphoma, 2022-10, Vol.63 (10), p.2383-2392

2022

Link zum Volltext

Verfügbarkeit prüfen

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.147-147, Article 147

2023

Link zum Volltext

Verfügbarkeit prüfen

Recognition of early mortality in multiple myeloma by a prediction matrix

American journal of hematology, 2017-09, Vol.92 (9), p.915-923

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

British journal of haematology, 2021-04, Vol.193 (1), p.93-100

2021

Link zum Volltext

Verfügbarkeit prüfen

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

British journal of haematology, 2019-12, Vol.187 (5), p.602-614

2019

Link zum Volltext

Verfügbarkeit prüfen

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Future oncology (London, England), 2024-01, Vol.20 (3), p.131-143

2024

Link zum Volltext

Verfügbarkeit prüfen

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

Annals of hematology, 2018-12, Vol.97 (12), p.2425-2436

2018

Link zum Volltext

Verfügbarkeit prüfen

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Drugs (New York, N.Y.), 2018-06, Vol.78 (8), p.853-855

2018

Link zum Volltext

Verfügbarkeit prüfen

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Future oncology (London, England), 2019-05, Vol.15 (13), p.1411-1428

2019

Link zum Volltext

Verfügbarkeit prüfen

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma : A phase III multicenter randomized trial

Cancer, 2006-02, Vol.106 (4), p.848-858

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 332

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(298)
Mit Volltextzugriff
(280)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Improved differential diagnosis of intracardiac and extracardiac shunts using acoustic intensity mapping of saline contrast studies

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

GIRK currents in VTA dopamine neurons control the sensitivity of mice to cocaine-induced locomotor sensitization

Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies

Analytical similarity as base for rituximab biosimilars in lymphoid malignancies in the clinic: a PF-05280586 case study

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

Demystifying biosimilars: development, regulation and clinical use

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Recognition of early mortality in multiple myeloma by a prediction matrix

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry

Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry

class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

Authors’ Reply to Pires et al.: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma

Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma : A phase III multicenter randomized trial

Aktive Filter

Suchergebnisse filtern